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Abstract
The prevalence of type 2 diabetes mellitus and of the metabolic syndrome is
rising worldwide and reaching epidemic proportions. These pathologies are
associated with significant morbidity and mortality, in particular with an excess
of cardiovascular deaths. Type 2 diabetes mellitus and the cluster of pathologies
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including insulin resistance, central obesity, high blood pressure, and hypertri-
glyceridemia that constitute the metabolic syndrome are associated with low
levels of HDL cholesterol and the presence of dysfunctional HDLs. We here
review the epidemiological evidence and the potential underlying mechanisms
of this association. We first discuss the well-established association of type
2 diabetes mellitus and insulin resistance with alterations of lipid metabolism
and how these alterations may lead to low levels of HDL cholesterol and the
occurrence of dysfunctional HDLs. We then present and discuss the evidence
showing that HDL modulates insulin sensitivity, insulin-independent glucose
uptake, insulin secretion, and beta cell survival. A dysfunction in these actions
could play a direct role in the pathogenesis of type 2 diabetes mellitus.
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1 Type 2 Diabetes Mellitus and the Metabolic Syndrome
Diabetes mellitus (DM) is characterized by increased fasting and/or postprandial
glucose levels. The disease had been known for many centuries (Laios et al. 2012).
Its etiology1 however started to be unraveled in the late nineteenth century/early
twentieth century. During this period, it was eventually discovered that a compound
in pancreatic extracts (later identified to be insulin) could cure young diabetic
patients (Banting et al. 1922). From the early work of H. P. Himsworth in 1936, a
concept emerged that diabetes could be divided into what he termed “insulin
sensitive” and “insulin insensitive” [the pioneering work of Himsworth is nicely
portrayed in a historical perspective written by Gerald Reaven (Reaven 2005)]. But
it is only once a reliable radioimmunoassay became available to measure
circulating insulin levels (Bray 1996) that it was realized that some patients
suffered from a disease associated with low to undetectable insulin levels and
prone to ketoacidosis (type 1 DM [T1DM]), while others, the vast majority, had
high circulating insulin levels despite increased glucose levels (type 2 DM
[T2DM]) (Inzucchi 2012). Patients with T2DM are often overweight and obese,
and their diabetes develops later in life. These patients are characterized as having
insulin resistance (IR), i.e., a decreased response of insulin-sensitive tissues to the
effects of the hormone, in particular its ability to induce glucose uptake. Insulin
resistance is usually associated with compensatory hyperinsulinemia in an attempt
to maintain normoglycemia. Insulin resistance is a hallmark of T2DM as well as of
overweight and obesity. Insulin resistance precedes the development of T2DM, and
it is once that the beta cell can no longer compensate to the insulin resistance that
the full-blown disease with hyperglycemia develops (Tabak et al. 2009). Gerald
1 The study of causes or origins (of a disease).
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Reaven, in his seminal Banting Lecture in 1988 (Reaven 1988), summarized his
work that put insulin resistance not only at the center of diabetes research but
proposed that insulin resistance may directly contribute to the increased risk of
coronary artery disease associated with T2DM or obesity. In this chapter, he
suggested that IR and hyperinsulinemia were, together with increased VLDL/
triglyceride levels, low HDL cholesterol levels, and hypertension, directly
associated with and responsible for the development of diabetes. He termed “syn-
drome2 X” the clustering of these features. Syndrome X was also named “insulin
resistance syndrome” but is now generally called “metabolic syndrome.” This
syndrome corresponds to a cluster of increased abdominal obesity (a good proxy
of insulin resistance), increased blood glucose levels, high blood pressure and
elevated triglycerides, and low HDL cholesterol levels. Several definitions of the
Table 1 Definitions of the metabolic syndrome
NCEP ATP III WHO (1998) IDF (2005)
Criteria Three of the
following
Presence of DM, IGF, IGT,
or insulin resistance and
two of the following
Central obesity
(ethnicity specificity)
and two of the
following
Anthropometric
data
Waist
circumference
>102 cm (men)
>88 cm (women)
WHR> 0.9 (men)
WHR> 0.85 (women)
and/or
BMI> 30 kg/m2
Lipids TG 1.7 mmol/l
and/or
HDL-
C< 1.03 mmol/l
(men)
or< 1.29 mmol/l
(women)
or treatment for
these specific lipid
abnormalities
TG 1.7 mmol/l and/or
HDL-C< 0.9 mmol/l
(men) or <1.0 mmol/l
(women)
TG 1.7 mmol/l
and/or
HDL-C< 1.03 mmol/
l (men)
or< 1.29 mmol/l
(women)
or treatment for these
specific lipid
abnormalities
Blood pressure 130/85 mmHg
or treatment
140/90 mmHg 130/85 mmHg
r treatment
Blood glucose FPG 5.6 mmol/l
or treatment
FPG 5.6 mmol/l or
treatment
Others Urinary albumin
excretion 20 μg/min or
albumin/creatinine
ratio 30 mg/g
BMI body mass index, DM diabetes mellitus, FPG fasting plasma glucose, HDL-C high-density
lipoprotein cholesterol, IDF International Diabetes Federation, IFG impaired fasting glucose, IGT
impaired glucose tolerance, NCEP National Cholesterol Education Program, TG triglycerides,
WHO World Health Organization, WHR waist-hip ratio
2 A group of symptoms that collectively indicate or characterize a disease.
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metabolic syndrome have been proposed with the National Cholesterol Education
Program Adult Treatment Panel III (NCEP ATP III) definition being the one most
widely used. TheWorld Health Organization (WHO) and the International Diabetes
Federation (IDF) have suggested other definitions. Table 1 summarizes these
various definitions. These current definitions, albeit arbitrary in the cutoffs that
were chosen for the different variables included, are intended to provide a useful
tool for clinicians to identify individuals at increased risk for the development of
T2DM, atherosclerotic cardiovascular disease, and cardiovascular death. T2DM
and the metabolic syndrome are characterized not only by insulin resistance but
also by a dyslipidemia that includes high triglyceride and low HDL cholesterol
levels. With the presence of small dense LDLs in T2DM, these lipid abnormalities
substantially contribute to the increased cardiovascular morbidity and mortality
associated with these conditions (Grundy 2012). Several epidemiological studies
have clearly shown that these lipid abnormalities are present before the develop-
ment of T2DM. Furthermore, longitudinal studies have provided evidence that
these abnormalities represent an independent risk factor for T2DM (von
Eckardstein et al. 2000). Hence, the concept has emerged that lipid abnormalities
associated with IR and the metabolic syndrome are not only bystanders of the
metabolic dysfunctions but contribute directly to the progression to type DM.
2 Low HDL Cholesterol Levels in Diabetes and Metabolic
Syndrome
T2DM and the metabolic syndrome are characterized by the presence of an
atherogenic dyslipidemia typically including low HDL cholesterol, hypertrigly-
ceridemia, and increased small dense LDL blood concentrations. Individuals with
low HDL cholesterol are often insulin resistant and at increased risk of developing
T2DM (Li et al. 2014; von Eckardstein and Sibler 2011). T2DM, the metabolic
syndrome, and IR are characterized by hyperinsulinemia and increased free fatty
acids (FFA). Both insulin resistance and FFAs appear to contribute to the patho-
genesis associated with decreased HDL levels (Rohrer et al. 2004).
2.1 Insulin Resistance, Hypertriglyceridemia, and Decreased
HDL Cholesterol Levels
Insulin has pleiotropic effects on lipid metabolism, in particular on the metabolism
of HDLs and the TG-rich VLDLs. In rats, insulin can acutely decrease the hepatic
production of ApoB100 (Chirieac et al. 2000), the apolipoprotein required for
VLDL assembly, by favoring ApoB100 degradation. In the Hep2G liver cell line,
insulin also decreases the levels of microsomal TG transfer protein that is essential
for VLDL synthesis and secretion (Lin et al. 1995). Insulin could therefore nega-
tively affect the hepatic production of VLDL. However, the situation is more
complex than this because there are two VLDL subtypes that are differentially
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regulated by insulin, the larger and more buoyant VLDL1 particles and the smaller
and denser VLDL2 particles. VLDL2 particles are intermediates in the synthesis of
VLDL1 in the liver, but they can also be secreted directly by this organ. Addition-
ally, VLDL2 can be generated in the circulation from VLDL1 through lipoprotein
lipase activity (Taskinen 2003). Insulin does not appear to affect the hepatic
production of VLDL2 (at least not in humans, see below) but seems to only inhibit
hepatic VLDL1 production by inhibiting the conversion of VLDL2 into VLDL1
(Taskinen 2003). VLDL1 particles are seen by some authors as “liver-derived”
chylomicron-like particles (Taskinen 2003). It makes sense therefore that insulin
inhibits their production following meals in a situation where chylomicrons are
produced by the intestine. In contrast, VLDL1 particle production could be favored
in the fasting state. While insulin inhibits VLDL1 production, it favors the hepatic
production of VLDL2 particles because insulin can increase the activity of the
sterol regulatory element-binding protein (SREBP) 1c transcription factor that
induces the expression of enzymes required for fatty acid and TG synthesis, such
as fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) (Horton
et al. 2002). However, insulin was not found to modulate VLDL2 blood levels in
humans (Malmstrom et al. 1997a, b). The physiological importance of the regula-
tion of fatty acid and TG synthesis by insulin on VLDL production is therefore
unclear. In type 2 diabetic individuals (i.e., in the presence of an insulin-resistant
state), insulin is no longer able to inhibit VLDL1 production (Malmstrom
et al. 1997a), and this can thus favor overall VLDL hepatic secretion. This presum-
ably contributes to the hypertriglyceridemia seen in type 2 diabetic and metabolic
syndrome patients (Brown and Goldstein 2008). In addition, hyperinsulinemia
resulting from insulin resistance can enhance SREBP1c transcription and thereby
microRNA33b (miR33b) that is encoded by an intron of the SREBP1c gene. Both
SREBP1c and miR33b can drive VLDL production and favor hypertriglyceridemia
by stimulating fatty acid and triglyceride synthesis (Rayner et al. 2011).
A high production of VLDLs can decrease the stability of HDL particles by
increasing the transfer of TG from TG-rich particles to HDLs via the activity of the
cholesteryl ester transfer protein (CETP) enzyme (Rashid et al. 2003). This is one
possible mechanism linking high TG blood levels with decreased HDL cholesterol
levels. Insulin participates in the clearance of TG from TG-rich lipoproteins by
stimulating the secretion of lipoprotein lipase (LPL) in certain adipose tissues (e.g.,
subcutaneous depot) (Fried et al. 1993). Consequently, insulin resistance would
lead to increased circulating TG-rich particles and augmented TG loading of HDLs.
Additionally, reduced TG hydrolysis in VLDLs and chylomicrons will decrease the
release of surface remnants which contribute to the maturation of HDL (Eisenberg
1984; Rashid et al. 2003). These two effects combined—decreased surface remnant
production and enhanced CETP activity—favor the reduction in HDL cholesterol
levels via the mechanism mentioned above (i.e., decreased HDL stability due TG
enrichment of the particle).
Insulin has the potential to directly affect HDL production by the liver, either in
a positive or in a negative manner. In the Hep2G liver cell line, insulin can stimulate
the expression of apolipoprotein A-I (ApoA-I) (Murao et al. 1998), the most
HDLs, Diabetes, and Metabolic Syndrome 409
abundant apolipoprotein in HDLs (Eisenberg 1984; Rye and Barter 2012), raising the
possibility that hepatic insulin resistance contributes to decreased production of
HDLs. The relevance of this effect has however not been validated in vivo. In
contrast, insulin may also negatively impact on hepatic HDL production by enhanc-
ing miR33 transcription. Indeed, miR33 suppresses the production of the adenosine
triphosphate-binding cassette transporter A1 (ABCA1) at the posttranscriptional level
and thereby compromises phospholipid and cholesterol efflux needed for HDL
formation (Besler et al. 2012; Rader 2006; Rayner et al. 2011; Tang and Oram 2009).
2.2 FFAs and Decreased HDL Levels
In vitro, FFAs decrease the expression of SREBP1c by inhibiting the transcriptional
activity of liver X receptor (LXR) (Ou et al. 2001; Yoshikawa et al. 2002). This
represents a negative feedback loop ensuring that the production of VLDLs occurs
when there is a need to deliver TGs to peripheral tissues (muscles, adipose tissue,
etc.). Reduction in LXR activity, and consequently VLDL production, would be
expected to lead to increased HDL cholesterol blood levels as a result of increased
HDL stability. However, in the liver, unsaturated FFAs inhibit the expression of
ABCA1 (Uehara et al. 2002). Moreover, free fatty acids stimulate the proteasomal
degradation of ABCA1 (Wang and Oram 2005, 2007). So even though FFAs can
lower the production of hepatic triglycerides, which will favor HDL stability, FFAs,
at the same time, directly inhibit the generation of HDL particles.
2.3 HDL Metabolism, Subclasses, and Catabolism
Nascent HDLs are the precursors of the mature HDL3 and HDL2 particles. They are
generated from lipid-free ApoA-I that acquires phospholipids and cholesterol
extracellularly. ABCA1-mediated lipid efflux from cells is important for this initial
lipidation. Further acquisition of lipids and subsequent LCAT-driven cholesterol
esterification leads to the formation of mature HDL3 particles. These particles can
absorb more phospholipids and free cholesterol by a mechanism involving ABCG1.
Altogether, this transforms the HDL3 particles into larger and less dense HDL2
particles. Like ABCA1, this transporter is regulated by LXR and hence suppressed
by unsaturated fatty acids at the transcriptional level (Uehara et al. 2007) so that the
production of larger HDL2 is compromised. In addition, the conversion of HDL2
into HDL3 is enhanced in diabetic dyslipidemia by increased activities of CETP and
hepatic lipase: First, the transfer rate of cholesteryl esters from HDL to VLDL in
normal individuals depends on the concentration of CE acceptors, that is, VLDL
particles, but not on CETP activity (Mann et al. 1991). However, in individuals with
hypertriglyceridemia, cholesteryl ester transfer from HDL to VLDL can be aug-
mented by increasing CETP plasma activity (Mann et al. 1991). Second, HL and
endothelial lipase can convert HDL2 particles back to HDL3 particles that begin a
new cycle of maturation or are further degraded by the liver or cleared through the
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kidneys (Borggreve et al. 2003; Ginsberg 1998; Rader 2006). HL activity is increased
in T2DM (Tan et al. 1999) and contributes to the production of smaller and denser
HDL particles (i.e., HDL2 to HDL3) that are then catabolized as indicated above.
3 Does HDL Play a Causal Role in the Pathogenesis
of Diabetes?
Several epidemiological studies have shown the association between low plasma
concentrations of HDL-C and increased risks not only of CHD but also T2DM
(Di et al. 2009; von Eckardstein et al. 2000).
We have seen that some of the metabolic perturbations (hyperglycemia,
hypertriglyceridemia, etc.) associated with diabetes (and the metabolic syndrome)
are mechanistically linked to decreased HDL cholesterol levels in blood. Tradition-
ally, a reduced plasmatic level of HDL cholesterol has been interpreted to be the
result of such metabolic perturbations, which are already present in the prediabetic
state, and hence an innocent bystander of T2DM. However, several more recent
studies suggest that HDLs help to maintain euglycemia via both insulin-dependent
and insulin-independent pathways (Drew et al. 2012; von Eckardstein and Sibler
2011). The infusion of artificially reconstituted HDL (rHDL) was found to improve
glycemia in patients with T2DM (Drew et al. 2009). In a post hoc analysis of data
from diabetic participants in the ILLUMINATE trial, the addition of the CETP
inhibitor torcetrapib to atorvastatin was found to increase HDL-C and to improve
glycemic control (Barter et al. 2011). Several in vitro and animal experiments
provided evidence that HDL improves the function and survival of beta cells as
well as glucose-lowering metabolism in the muscle, liver, and adipose tissue (Drew
et al. 2012; von Eckardstein and Sibler 2011; von Eckardstein and Widmann 2014).
In mice, the absence of ApoA-I leads to hyperinsulinemia and hyperglycemia as
well as altered responses to insulin tolerance tests. Vice versa, ApoA-I transgenic
mice exhibit lower fasting glucose levels and improved glucose tolerance test
compared with wild-type mice (Han et al. 2007; Lehti et al. 2013). These data
point to a modulating role of HDLs in maintaining normal glucose homeostasis.
Moreover, genetically increased HDL cholesterol and ApoA-I levels in mice
prevented high-fat diet-induced glucose homeostasis impairment (Lehti et al. 2013).
Although it remains to be determined whether this is related to differences in
skeletal muscle insulin resistance, adipose tissue mass, or differences in beta cell
function, these data obtained in mice indicate that ApoA-I plays a modulatory role
in the regulation of glucose homeostasis. This notion is also supported by studies in
humans displaying altered HDL metabolism due to polymorphisms in the ApoA-I
and ABCA1 genes that have been associated with increased risk of diabetes and
impaired glucose uptake (Morcillo et al. 2005; Villarreal-Molina et al. 2008).
Heterozygotes for rare mutations in the ABCA1 gene that profoundly decrease
HDL-C levels were found to be less glucose tolerant than their unaffected relatives
(Vergeer et al. 2010). However, it should also be noted that larger population
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studies did not find any association between heterozygosity for ABCA1 mutations
and risk of diabetes (Schou et al. 2012).
3.1 Effects of HDL on Obesity
Augmented adipose tissue content is the hallmark of obesity. There is increasing
evidence that HDL or ApoA-I regulate adipose tissue content. In humans,
polymorphisms within the ApoA-I gene have been associated with increased risk
of developing obesity and hypertension in a Brazilian cohort (Chen et al. 2009).
More evidence for a potential role of HDL cholesterol on adipose tissue content
regulation and obesity stems from genetic mouse models either lacking or
overexpressing ApoA-I or treated with ApoA-I mimetic peptides. For example,
ApoA-I-deficient mice have an increased fat content (Han et al. 2007). On the other
hand, mice overexpressing ApoA-I or treated with the D-4F ApoA-I mimetic
peptide3 (Navab et al. 2005; Van Lenten et al. 2009) showed decreased white
adipose tissue mass gain when fed a high-fat diet for 3 months (Ruan et al. 2011).
ApoA-I transgenic and D-4F-treated mice had slightly improved insulin sensitivity
when fed a high-fat diet compared to wild-type mice. This was associated with
increased energy expenditure as measured in metabolic cages and related to
increased expression of uncoupling protein 1 (UCP-1) in brown adipose tissue
and AMPK phosphorylation (Ruan et al. 2011). Consistent with these results is
the observation that administration of D-4F and L-4F in high-fat diet-fed mice
reduced weight gain and improved insulin sensitivity when compared with
age-matched vehicle-treated mice (Peterson et al. 2009). Taken together, these
observations implicate a potential antiobesity effect of ApoA-I. In another study,
ApoA-I gene transfer in the liver of mice increased adiponectin plasma levels and
potently attenuated the rise of triglycerides and free fatty acids induced by lipopoly-
saccharide administration (Van Linthout et al. 2010). In vitro, incubation of 3 T3-
L1 adipocytes with HDLs induced adiponectin expression in a phosphatidy-
linositol-3-kinase-dependent manner (Van Linthout et al. 2010). This set of
experiments showed that ApoA-I and HDLs affect adipose tissue metabolism and
adiponectin expression. ApoA-I and HDL have been shown to have anti-
inflammatory properties in adipocytes similarly to what has been observed in
macrophages and endothelial cells. It was found that both HDL and ApoA-I inhibit
palmitate-mediated gene induction of pro-inflammatory chemotactic factor (e.g.,
monocyte chemotactic protein-1, serum amyloid A3) in cultured adipocytes
(Umemoto et al. 2013). Furthermore, there was a reduction in chemotactic factor
3 This peptide, albeit lacking any sequence homology to ApoA-I, forms a class A amphipatic helix
similar to those found in ApoA-I. D-4F favors HDL formation and has anti-inflammatory and anti-
atherogenic properties. The “D” in D-4F indicates that the peptide was synthesized with nonnatural
D-amino acids (if synthesized with the natural L-amino acids, the peptide is called L-4F). D-amino
peptides are very stable in biological fluids as they are not efficiently recognized by proteases
(Chorev and Goodman 1995; Fischer 2003; Michod et al. 2009).
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expression and macrophage accumulation in ApoA-I transgenic mice fed a high-fat
diet compared to similarly treated control mice (Umemoto et al. 2013). Because
macrophage accumulation and adipose tissue inflammation are strongly correlated
with insulin resistance, these observations provide potential implications for the
prevention and management of insulin resistance.
The molecular mechanisms involved in the antiobesity effects of ApoA-I are
poorly understood. A recent suggestion is that ApoA-I and HDL might regulate
autophagy in adipocytes. Decreased autophagy in pre-adipocytes has been
associated with a preferential differentiation into “brown-like” adipocytes and
improved energy expenditure, with reduced generation of white adipose tissue
that serves mostly as an energy storage tissue (Wang and Peng 2012). Another
potential mechanism is the direct capture of cholesterol from adipocytes by HDLs
or ApoA-I (von Eckardstein and Sibler 2011; Zhang et al. 2010).
3.2 Effects of HDL on Insulin Sensitivity and Glucose Utilization
by Skeletal Muscle
There is increasing evidence that HDLs regulate glucose uptake in insulin-sensitive
tissues. In a set of elegant experiments in patients with T2 DM, Drew et al. showed
that reconstituted HDL (rHDL) infusion over 4 h induced larger decreases of
plasma glucose levels than placebo. This effect was associated with increased
insulin secretion (Drew et al. 2009). In the C2C12 myocyte cell line, ApoA-I
increased glucose uptake in an insulin-independent manner and also potentiated
insulin- and adiponectin-induced glucose uptake (Han et al. 2007). ApoA-I effects
on glucose uptake were dependent on the endocytosis of the protein and subsequent
phosphorylation of AMPK and acetyl-coenzyme A carboxylase (ACC). In agree-
ment with these observations, ApoA-I also increased glucose uptake in isolated
mouse soleus muscle. Furthermore, in ApoA-I-deficient mice, AMPK phosphory-
lation status was decreased in skeletal muscle as well as in liver (Han et al. 2007).
These data suggest that in vivo, ApoA-I levels are able to regulate AMPK phos-
phorylation. In ApoA-I-/- mice, expression of liver enzymes regulating gluconeo-
genesis (e.g., phosphoenolpyruvate carboxykinase, glucose-6-phosphatase) was
also increased (Han et al. 2007), suggesting that hepatic glucose output is increased
in animals lacking the main HDL apolipoprotein.
HDLs were also found to directly enhance glucose oxidation by increasing
glycolysis and mitochondrial respiration rate in C2C12 muscle cells (Lehti
et al. 2013). ATP synthesis was blunted in mitochondria isolated from the gastroc-
nemius muscle of ApoA-I knockout mice. Endurance capacity of ApoA-I knockout
mice was reduced upon exercise exhaustion testing. Conversely, mice
transgenically overexpressing human ApoA-I exhibited increased lactate levels,
reduced fat mass, and protection against age-induced decline of endurance capacity.
Circulating levels of fibroblast growth factor 21, a factor potentially involved in
mitochondrial respiratory chain activity and inhibition of white adipose lipolysis,
were significantly reduced in ApoA-I transgenic mice (Lehti et al. 2013).
HDLs, Diabetes, and Metabolic Syndrome 413
3.3 The Beneficial Effects of HDL in Pancreatic Beta Cells
HDLs also exert potentially antidiabetogenic functions on pancreatic beta cells by
potently inhibiting stress-induced cell death and possibly enhancing glucose-
stimulated insulin secretion.
3.3.1 Beneficial Effects of HDL on Insulin Secretion
In vivo and in vitro evidence suggests that HDLs support the insulin secretory
capacity of beta cells (Drew et al. 2012). Infusion of reconstituted HDLs in type
2 diabetes patients increased their HOMA-B index, an indirect measurement of
pancreatic beta cell function (Drew et al. 2009). Also, the increase of HDL
cholesterol levels in healthy volunteers treated for 2 weeks with a CETP inhibitor
was found to increase postprandial insulin and C-peptide plasma levels (Siebel
et al. 2013). The plasma of the CETP inhibited volunteers but not the CETP
inhibitor itself also showed an increased capacity to enhance glucose-stimulated
insulin secretion from MIN6 cells.
In vitro data on the effects of HDL or ApoA-I on insulin secretion are however
controversial. Fryirs and collaborators showed that stimulation of the Min6
insulinoma cell line for 1 h with lipid-free recombinant ApoA-I, ApoA-II, or
discoidal reconstituted HDLs dose-dependently increased both basal and glucose-
stimulated insulin secretion (Fryirs et al. 2010). By RNA interference, the authors
showed that the stimulatory effect of lipid-free ApoA-I and reconstituted HDLs on
insulin secretion depended on ABCA1 and ABCG1, respectively (Fryirs
et al. 2010). By contrast, other experiments in Min6 cells as well as islets of mice
and humans did not find conclusive evidence that HDL enhances insulin production
or basal and glucose-stimulated insulin secretion (Abderrahmani et al. 2007;
Roehrich et al. 2003; Rutti et al. 2009). Therefore and considering the supra-
physiological concentrations of lipid-free ApoA-I used by Fryirs et al., it appears
uncertain of whether HDLs have a direct effect on the insulin secretory capacity of
beta cells.
However, there is good evidence that ABCA1 and ABCG1 modulate insulin
secretion from pancreatic beta cells. Mice with a targeted knockout of ABCA1 in
pancreatic beta cells and crossbred with hypercholesterolemic LDL-receptor
knockout mice were found to be less glucose tolerant than LDL-receptor knockout
only mice (Brunham et al. 2007). The beta cell-specific ABCA1 knockout mice also
showed reduced insulin secretion in response to glucose administration. Islets
isolated from these mice showed altered cholesterol homeostasis and impaired
insulin secretion in vitro (Brunham et al. 2007). In vitro, beta cells lacking
ABCA1 showed impaired depolarization-induced insulin granule release,
disturbances in membrane micro-domain organization, and alteration in Golgi
and insulin granule morphology. Acute cholesterol depletion rescued the exocytotic
defect in beta cells lacking ABCA1, suggesting that elevated islet cholesterol
accumulation directly impairs granule fusion and insulin secretion (Kruit
et al. 2011). Posttranscriptional suppression of ABCA1 in beta cells by adenoviral
overexpression of miR33a and miR145 also led to increased cholesterol levels and
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to decreased glucose-stimulated insulin secretion (Kang et al. 2013; Wijesekara
et al. 2012). This compromised insulin secretion was again rescued by cholesterol
depletion. Inhibition of miR33a expression in apolipoprotein E knockout islets and
ABCA1 overexpression in beta cell-specific ABCA1 knockout islets rescued nor-
mal insulin secretion and reduced islet cholesterol (Wijesekara et al. 2012). ABCG1
knockout mice also show glucose intolerance due to reduced insulin secretion
(Sturek et al. 2010). In contrast to ABCA1 knockout, this defect was rescued by
the addition of cholesterol rather than by depletion of cholesterol (Sturek
et al. 2010). These studies show that a delicate balance of cholesterol
concentrations between different subcellular compartments must be achieved to
allow optimal beta cell functionality. As the consequence of the nonredundant roles
of ABCA1 and ABCG1 in beta cell activity, the combined inactivation of ABCA1
and ABCG1 increased intracellular cholesterol accumulation and induced inflam-
mation in beta cells and aggravated the diabetic phenotype found in the single
knockout animals (Kruit et al. 2012).
Taken together, these findings indicate that cholesterol homeostasis and its
regulation by ABCA1 and ABCG1 are critical for the secretory function of beta
cells. However, the human genetic data mentioned before do not unequivocally
support the findings made in the genetic mouse models. On the one hand, decreased
glucose-induced insulin secretion has been reported in ABCA1-deficient patients
with Tangier disease or heterozygous carriers of ABCA1 mutations (Koseki
et al. 2009; Vergeer et al. 2010). On the other hand, mutations in ABCA1 have
not been associated with increased risk of diabetes (Schou et al. 2012).
3.3.2 Effects of HDL on Pancreatic Beta Cell Survival and ER Stress
Several studies have shown that HDLs are very efficient in inhibiting apoptosis of
beta cells induced by a variety of stimuli including inflammatory cytokines, free
fatty acids (e.g., palmitate), thapsigargin, tunicamycin, or protein overexpression
(Abderrahmani et al. 2007; Petremand et al. 2012; Roehrich et al. 2003; Rutti
et al. 2009). Many of these stimuli induce endoplasmic reticulum (ER) stress. As
ER stress has been proposed to be a driving parameter in beta cell dysfunction and
death in the course of diabetes development (Eizirik et al. 2008; Oyadomari
et al. 2002; Volchuk and Ron 2010), the capacity of HDLs to protect beta cells
from ER stressors could be one mechanism underlying their potential ability to
prevent T2DM.
Pancreatic beta cells are professional secretory cells. Half of the proteins pro-
duced by these cells are insulin. These cells have therefore developed an extensive
ER network to fulfill their physiological function (Like and Chick 1970; Marsh
et al. 2001). In response to the development of insulin resistance, triggered by
obesity, for example, more insulin needs to be secreted by beta cells to compensate
for insulin resistance and to achieve proper glycemic control. Such a sustained
demand in insulin production can eventually cause ER dysfunction leading to
chronic ER stress. This may promote beta cell dysfunction and ultimately beta
cell death (Eizirik et al. 2008; Eizirik and Cnop 2010; Volchuk and Ron 2010).
There is a wealth of evidence demonstrating that HDLs activate antiapoptotic
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responses in beta cells (Abderrahmani et al. 2007; Cnop et al. 2002; Petremand
et al. 2009; Rutti et al. 2009). HDLs are particularly potent in inhibiting beta cell
death induced by ER stressors (Petremand et al. 2009; Rutti et al. 2009). Recently, it
was shown that HDLs maintain, despite the presence of ER stressors, a proper ER
morphology and functionality in terms of the capacity of the ER to fold proteins and
to allow protein trafficking out of the ER. Maintenance of the functionality of the
ER was shown to be required for the beta cell protective activity of HDLs
(Petremand et al. 2012). The ER stressors used included palmitate that is thought
to mimic pro-diabetogenic conditions found in individuals with impaired glucose
tolerance that are at risk of developing diabetes (Biden et al. 2004; Maedler
et al. 2001; Shimabukuro et al. 1998). While this work identified a cellular mecha-
nism mediating the beneficial effect of HDLs on beta cells against pro-diabetogenic
factors, the underlying molecular mechanisms remain largely unresolved.
The agonist for the potentially antidiabetic activity of HDL on beta cell apopto-
sis has not yet been identified. The available information is mostly of negative
nature. In beta cells, in contrast to endothelial cells, the SR-BI receptor is not
required for HDL-mediated antiapoptotic responses (Petremand et al. 2012; Rutti
et al. 2009). There is also no evidence that Akt, which plays a pivotal role in
mediating the antiapoptotic activity of HDL in endothelial cells, participates in the
protective function of HDLs in beta cells (Puyal et al. 2013). It appears therefore
that the molecular mechanisms underlying the antiapoptotic property of HDLs in
beta cells differ from those employed in endothelial cells. These mechanisms
remain unknown (von Eckardstein and Widmann 2014).
Conceivably, individual components of HDLs may mediate their protective
functions in beta cells. Actually, there is evidence that this could be the case. In
primary islets, IL1β-induced beta cell apoptosis can be inhibited by either the
delipidated HDL protein or the deproteinated lipid moieties of HDL as well as by
ApoA-I and by S1P (Rutti et al. 2009). This is a good indication that proteins and
lipids found in HDL particles carry pro-survival activities. However, pancreatic
islets do not only contain beta cells (70–80 %) but also alpha cells (15–20 %), delta
cells, PP cells, and immigrating blood-borne cells such as macrophages. Therefore,
it is not clear whether ApoA-I and S1P exert their antiapoptotic effects on beta cells
directly or indirectly, for example, by interfering with the release of proapoptotic
signals from non-beta cells. To distinguish direct from indirect effects and to
unravel the molecular basis for the antiapoptotic effects, it will be essential to
substitute the complex model of pancreatic islets with purified beta cells or surro-
gate beta cell lines.
Conclusion
HDL possibly enhances glucose-stimulated insulin secretion (Drew et al. 2012;
Fryirs et al. 2010; von Eckardstein and Sibler 2011) and reverses the
proapoptotic effects of native and oxidized LDLs, IL1β, or thapsigargin
(Abderrahmani et al. 2007; Petremand et al. 2012; Roehrich et al. 2003; Rutti
et al. 2009). In addition, HDL and ApoA-I promote glucose uptake and activate
AMP-kinase in primary human skeletal muscle cells and differentiated
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adipocytes by an insulin-independent way (Drew et al. 2009; Han et al. 2007;
Zhang et al. 2011) and enhance oxidative metabolism in skeletal muscle through
phosphorylation of acetyl-CoA carboxylase (Drew et al. 2009). Unfortunately,
the identity of the agonists and their cognate receptors as well as the elicited
signaling pathways and downstream targets of the antidiabetogenic HDL
activities are yet poorly resolved. Understanding these pathways is a prerequisite
for the development of drugs that stimulate or mimic the antidiabetic effects of
HDLs and thereby help to lower the risk, for example, in overweight patients, to
manifest T2DM.
Open Access This chapter is distributed under the terms of the Creative Commons Attribution
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are credited.
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